New obesity combo drug tested in small safety study
NCT ID NCT06972992
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tested a new drug called ASC47, given as a shot under the skin, combined with the weight-loss drug semaglutide in 28 adults with obesity. The study was double-blind and placebo-controlled, meaning some participants got a dummy shot. The main goal was to check safety and side effects, but researchers also measured weight changes over 10 weeks. Because this is an early-stage study, the focus is on whether the combination is safe enough to test further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASC47 injection plus semaglutide
What this could lead to
If it works, this could lead to a new combination treatment for obesity that helps people lose more weight than semaglutide alone.
What could go wrong
This is a very early Phase 1 trial with only 28 people, so results may not apply to everyone. The main goal is safety, not weight loss, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascletis Clinical Site
San Antonio, Texas, 78209, United States